Comparison of Metformin and Myoinositol In Improving Insulin Sensitivity of Women with Polycystic Ovarian Syndrome
DOI:
https://doi.org/10.51253/pafmj.v75iSUPPL-6.13185Keywords:
Blood Glucose, Blood Insulin, HOMA-IR, Metformin, Myoinositol, Polycystic ovarian syndromeAbstract
Objective: To determine the outcome of Metformin versus Myoinositol in women with polycystic ovarian syndrome.”
Study Design: Quasi-experimental study
Place and Duration of Study: Department of Obstetrics & Gynecology, Avicenna Medical Hospital Lahore for 06 months (Oct-2022 to March-2023).
Methodology: One hundred patients were enrolled and divided in two Groups. In Group A, females were given Myo-inositol. In Group B, females were given Metformin. After 24 weeks, blood sample was taken for assessment of HOMA-IR. Reports were assessed and HOMA-IR level was recorded. Reduction in HOMA-IR in blood after 24 weeks of treatment was calculated. Information was recorded in proforma and analyzed in SPSS 23.
Results: The mean age of females in Myoinositol Group was 29.76±9.11 years while the mean age of females in Metformin Group was 32.52±8.81 years. In Myoinositol Group, 13(26%) had primary infertility and 25(50%) had secondary infertility. In Metformin Group, 7(14%) had primary infertility and 28(56%) had secondary infertility. In Myoinositol Group, the mean HOMA-IR at baseline was recorded as 27.59±19.10 that was reduced to 21.28±15.38. In Metformin Group, the mean HOMA-IR at baseline was recorded as 24.13±12.32 that was changed to 16.55±7.56. The difference in both Groups at baseline was insignificant as well as after 24 weeks, however the HOMA-IR was less in Metformin Group (p-value >0.05).
Conclusion: Thus there is no difference in the HOMA-IR level whether Metformin is prescribed or Myoinositol is prescribed
Downloads
References
1. Mishra N, Verma R, Jadaun P. Study on the effect of berberine, Myoinositol, and Metformin in women with polycystic ovary syndrome: a prospective randomised study. Cureus. 2022; 14(1).
https://doi: 10.7759/cureus.21781.
2. Nas K, Tuu L. A comparative study between myo-inositol and Metformin in the treatment of insulin-resistant women. Eur Rev Med Pharmacol Sci. 2017; 21(2 Suppl): 77-82.
3. Tagliaferri V, Romualdi D, Immediata V, De Cicco S, Di Florio C, Lanzone A, et al. Metformin vs Myoinositol: which is better in obese polycystic ovary syndrome patients? A randomized controlled crossover study. Clin Endocrinol. 2017; 86(5): 725-30.
https://doi: 10.1111/cen.13304.
4. Zhao H, Xing C, Zhang J, He B. Comparative efficacy of oral insulin sensitizers Metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis. Reprod Health. 2021; 18(1): 171.
https://doi: 10.1186/s12978-021-01207-7.
5. Thalamati S. A comparative study of combination of Myo-inositol and D-chiro-inositol versus Metformin in the management of polycystic ovary syndrome in obese women with infertility. Int J Reprod Contracept Obstet Gynecol. 2019; 8(3): 825-30.
https://doi.org/10.18203/2320-1770.ijrcog20190498
6. Agrawal A, Mahey R, Kachhawa G, Khadgawat R, Vanamail P, Kriplani A. Comparison of Metformin plus Myoinositol vs Metformin alone in PCOS women undergoing ovulation induction cycles: randomized controlled trial. Gynecol Endocrinol. 2019; 35(6): 511-4.
https://doi: 10.1080/09513590.2018.1549656.
7. Facchinetti F, Orrù B, Grandi G, Unfer V. Short-term effects of Metformin and myo-inositol in women with polycystic ovarian syndrome (PCOS): a meta-analysis of randomized clinical trials. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology. 2019; 35(3): 198-206.
8. Sidra S, Tariq MH, Farrukh MJ, Mohsin M. Evaluation of clinical manifestations, health risks, and quality of life among women with polycystic ovary syndrome. PloS one. 2019; 14(10): e0223329.
9. Shah R. Emerging topics in cardiometabolic and psychologic sequelae, pathogenesis, and treatment of polycystic ovarian syndrome: A review. Children. 2019; 6(8): 89.
https://doi: 10.3390/children6080089.
10. Li Y, Wang Y, Liu H, Zhang S, Zhang C. Association between HOMA-IR and ovarian sensitivity index in women with PCOS undergoing ART: A retrospective cohort study. Front Endocrinol. 2023; 14.
https://doi: 10.3389/fendo.2023.1117996.
11. Nehra J, Kaushal J, Singhal SR, Ghalaut VS. A comparative study of myo inositol versus Metformin on biochemical profile in polycystic ovarian syndrome in women. Int J Pharma Sci Res. 2017; 8(4): 1664.
https://doi: 10.13040/IJPSR.0975-8232.8(4).1664-70
12. Anu M, Saraswathi K, David PEJ. A comparative study of myo-inositol versus Metformin in women with polycystic ovary syndrome. Ann Roman Soc Cell Biol. 2021:3770-83.
13. Gudović A, Bukumirić Z, Milincic M, Pupovac M, Andjić M, Ivanovic K, et al. The comparative effects of myo-inositol and Metformin therapy on the clinical and biochemical parameters of women of normal weight suffering from polycystic ovary syndrome. Biomedicines. 2024; 12(2): 349.
https://doi: 10.3390/biomedicines12020349.
14. De Leo V, Musacchio MC, Cappelli V, Di Sabatino A, Tosti C, Leo PP. A combined treatment with myo-inositol and monacolin k improve the androgen and lipid profiles of insulin-resistant PCOS patients. J Metabolic Synd. 2013; 2(127): 2167-0943.
https://doi:10.4172/2167-0943.1000127
15. Fruzzetti F, Perini D, Russo M, Bucci F, Gadducci A. Comparison of two insulin sensitizers, Metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS). Gynecol Endocrinol. 2017; 33(1): 39-42.
https://doi: 10.1080/09513590.2016.1236078.
16. Shokrpour M, Foroozanfard F, Afshar Ebrahimi F, Vahedpoor Z, Aghadavod E, Ghaderi A, et al. Comparison of myo-inositol and Metformin on glycemic control, lipid profiles, and gene expression related to insulin and lipid metabolism in women with polycystic ovary syndrome: a randomized controlled clinical trial. Gynecol Endocrinol. 2019; 35(5): 406-11.
https://doi: 10.1080/09513590.2018.1540570.
17. Tagliaferri V, Romualdi D, Immediata V, De Cicco S, Di Florio C, Lanzone A, et al. Metformin vs Myoinositol: which is better in obese polycystic ovary syndrome patients? A randomized controlled crossover study. Clin Endocrinol. 2017; 86(5): 725-30.
https://doi: 10.1111/cen.13304.
18. Angik R, Jajoo SS, Hariharan C, Chimote A. A comparative study of metabolic and hormonal effects of Myoinositol vs. Metformin in women with polycystic ovary syndrome: a randomised controlled trial. Int J Reprod Contracept Obstet Gynecol. 2015; 4(1): 189-95.
19. Awalekar J, Awalekar C, Jadhav V, Chivate C, Patwardhan M. Effect of Metformin & Myoinositol & life style modification in patients of polycystic ovarian disease (PCOD). Int J Biomed Res. 2015; 6(09): 698-704. https://doi:10.7439/ijbr.v6i9.2519
20. Nabi S, Guleria R. Comparison of Myoinositol and Metformin in women with polycystic ovarian syndrome. Indian J Clin Pract. 2020;30(11):1044-9.
21. Facchinetti F, Orru B, Grandi G, Unfer V. Short-term effects of Metformin and myo-inositol in women with polycystic ovarian syndrome (PCOS): a meta-analysis of randomized clinical trials. Gynecol Endocrinol. 2019; 35(3): 198-206. https://doi: 10.1080/09513590.2018.1540578.
22. Thalamati S. A comparative study of combination of Myo-inositol and D-chiro-inositol versus Metformin in the management of polycystic ovary syndrome in obese women with infertility. Int J Reprod Contracept Obstet Gynecol. 2019; 8(3): 825-9.
https://doi: http://dx.doi.org/10.18203/2320-1770.ijrcog20190498
23. Agarwal N, Kulshrestha V, Kumar D, Kachhawa G, Kumar A, Kriplani A, et al. Myoinositol versus Metformin in treating polycystic ovary syndrome in terms of improvement in clinical, hormonal and metabolic parameters: Which one and when? Indian Obstet Gynaecol. 2021; 11(2).
24. Kutenaei MA, Teshnizi SH, Ghaemmaghami P, Eini F, Roozbeh N. The effects of myo-inositol vs. Metformin on the ovarian function in the polycystic ovary syndrome: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2021; 25(7).
https://doi: 10.26355/eurrev_202104_25565.
25. Zhang J-Q, Xing C, He B. Short period-administration of myo-inositol and Metformin on hormonal and glycolipid profiles in patients with polycystic ovary syndrome: a systematic review and updated meta-analysis of randomized controlled trials. Eur Rev Med Pharmacol Sci. 2022; 26(6).
https://doi: 10.26355/eurrev_202203_28322.
Downloads
Published
License
Copyright (c) 2025 Sadia Awan, Gulfreen Waheed, Sana Navid
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
